- Home
- LRCX vs AMGN Comparison
LRCX vs AMGN Comparison
Compare LRCX & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRCX
- AMGN
- Stock Information
- Founded
- LRCX 1980
- AMGN 1980
- Country
- LRCX United States
- AMGN United States
- Employees
- LRCX N/A
- AMGN N/A
- Industry
- LRCX Industrial Machinery/Components
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LRCX Technology
- AMGN Health Care
- Exchange
- LRCX Nasdaq
- AMGN Nasdaq
- Market Cap
- LRCX 178.4B
- AMGN 150.8B
- IPO Year
- LRCX N/A
- AMGN N/A
- Fundamental
- Price
- LRCX $155.62
- AMGN $292.09
- Analyst Decision
- LRCX Buy
- AMGN Hold
- Analyst Count
- LRCX 26
- AMGN 15
- Target Price
- LRCX $143.54
- AMGN $313.57
- AVG Volume (30 Days)
- LRCX 11.9M
- AMGN 2.1M
- Earning Date
- LRCX 10-22-2025
- AMGN 11-04-2025
- Dividend Yield
- LRCX 0.67%
- AMGN 3.26%
- EPS Growth
- LRCX 46.65
- AMGN 110.88
- EPS
- LRCX 4.53
- AMGN 12.23
- Revenue
- LRCX $19,591,788,000.00
- AMGN $34,917,000,000.00
- Revenue This Year
- LRCX $11.54
- AMGN $8.90
- Revenue Next Year
- LRCX $10.96
- AMGN $1.79
- P/E Ratio
- LRCX $34.34
- AMGN $23.88
- Revenue Growth
- LRCX 25.66
- AMGN 12.88
- 52 Week Low
- LRCX $56.32
- AMGN $253.30
- 52 Week High
- LRCX $158.25
- AMGN $335.88
- Technical
- Relative Strength Index (RSI)
- LRCX 68.77
- AMGN 50.10
- Support Level
- LRCX $136.86
- AMGN $293.14
- Resistance Level
- LRCX $158.25
- AMGN $303.85
- Average True Range (ATR)
- LRCX 5.06
- AMGN 5.52
- MACD
- LRCX 0.37
- AMGN -0.88
- Stochastic Oscillator
- LRCX 90.14
- AMGN 24.57
About LRCX Lam Research Corporation
Lam Research is one of the largest semiconductor wafer fabrication equipment manufacturers in the world. It specializes in deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.